Amicus Therapeutics Inc.
This article was originally published in Start Up
Amicus Therapeutics Inc. believes it can rescue enzymes and other proteins containing mutations that result in misfolding, to restore their normal function and intervene in disease states. It's developing therapeutics for certain orphan indications, and plans to expand into other indications in which a genetic mutation results in sub-normal protein expression.
You may also be interested in...
CombinatoRx's platform screens combinations of known drugs to find pairs that could deliver a one-two punch to diseases such as cancer and rheumatoid arthritis.
NutraGenomics Inc. is using a systems approach to identify diet-responsive genes and SNPs involved in chronic diseases such as Type 2 diabetes, obesity, atherosclerosis, and certain cancers, using proprietary mouse models to examine dietary effects on genes, proteins, transcription, and metabolism.
Paths to commercialization are uncertain in nutrigenomics, an emerging science which seeks to identify gene-food interactions that differ among subpopulations and between individuals and to personalize diets to prevent disease.